Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioCorRx Inc.BICX · Entity 8179 | Director · President · 10% owner | April 24, 2024 | January 31, 2025 |
| RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.OPP · Entity 6374 | Exec Comm Mbr: OPP Subadviser | September 27, 2016 | September 27, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioCorRx Inc.
Report date April 24, 2024 · Filed January 31, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 2,511,940 |
Ending reported balance
After 2024-12-31 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2024-04-24 · Other · Acquired 460,477 · Balance 1,083,293 F1: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated April 24, 2024 (the "April 2024 Exchange Agreement"). Pursuant to the April 2024 Exchange Agreement, Mr. Lucido agreed to the exchange of a promissory note then outstanding in the amount of $446,426 and the accrued interest on such promissory note of $7,858 and director fees of $90,000 for 460,477 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance. Row 2 · 2024-07-31 · Grant · Acquired 32,092 · Balance 1,115,385 F2: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.5193. Row 3 · 2024-08-30 · Grant · Acquired 55,559 · Balance 1,170,944 F3: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30. Row 4 · 2024-09-30 · Grant · Acquired 52,085 · Balance 1,223,029 F4: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32. Row 5 · 2024-09-30 · Grant · Acquired 15,625 · Balance 1,238,654 F5: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019 (the "Director Agreement"), by and between the Company and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32. Row 6 · 2024-10-14 · Grant · Acquired 1,105,218 · Balance 2,343,872 F6: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated October 14, 2024 (the "October 2024 Exchange Agreement"). Pursuant to the October 2024 Exchange Agreement, Mr. Lucido agreed to the exchange the aggregate amount of $387,6700 of director's fees and loans to a subsidiary of the Company for 1,105,218 shares of Common Stock at a price of $0.36 per share based on the underlying value of the Common Stock at the date of issuance. Row 7 · 2024-10-31 · Grant · Acquired 55,556 · Balance 2,399,428 F7: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30. Row 8 · 2024-11-29 · Grant · Acquired 55,494 · Balance 2,454,922 F8: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.31. Row 9 · 2024-12-31 · Grant · Acquired 43,860 · Balance 2,498,782 F9: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38. Row 10 · 2024-12-31 · Grant · Acquired 13,158 · Balance 2,511,940 F10: These shares were issued to Mr. Lucido pursuant to the Director Agreement. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated April 24, 2024 (the "April 2024 Exchange Agreement"). Pursuant to the April 2024 Exchange Agreement, Mr. Lucido agreed to the exchange of a promissory note then outstanding in the amount of $446,426 and the accrued interest on such promissory note of $7,858 and director fees of $90,000 for 460,477 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance.
F2: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.5193.
F3: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30.
F4: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32.
F5: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019 (the "Director Agreement"), by and between the Company and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32.
F6: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated October 14, 2024 (the "October 2024 Exchange Agreement"). Pursuant to the October 2024 Exchange Agreement, Mr. Lucido agreed to the exchange the aggregate amount of $387,6700 of director's fees and loans to a subsidiary of the Company for 1,105,218 shares of Common Stock at a price of $0.36 per share based on the underlying value of the Common Stock at the date of issuance.
F7: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30.
F8: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.31.
F9: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38.
F10: These shares were issued to Mr. Lucido pursuant to the Director Agreement. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38.
RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.
Report date September 27, 2016 · Filed September 27, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2016-09-27 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2022 Filed Aug 29, 2022 16:16 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 500 | $2.18 | $1,090.00 |
DisclosureSEC source: 0001477932-22-006484 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,947 Read SEC document |
| June 30, 2022 Filed Jul 7, 2022 22:06 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004884 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,447 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:37 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-002042 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,355 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.55. Read SEC document |
| December 31, 2021 Filed Mar 2, 2022 20:10 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-001167 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,947 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.38. Read SEC document |
| October 19, 2021 Filed Oct 25, 2021 20:10 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 1,550 | $3.20 | $4,960.00 |
DisclosureSEC source: 0001477932-21-007564 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,806 Read SEC document |
| September 30, 2021 Filed Oct 25, 2021 20:10 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-007564 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,536 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.62. Read SEC document |
| June 30, 2021 Filed Jul 14, 2021 15:51 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-004602 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,155 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.13. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 17:44 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-002009 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,945 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.16. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 18:23 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 per share | 562,500 | $2.00 | $1,125,000.00 |
DisclosureSEC source: 0001477932-21-001163 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 562,500 F3 · kind: These shares were issued to the Louis C Lucido and Carolyn M. Lucido, or their Successors, as Trustee of the Lucido Family Trust, Dated May 23, 2017 (the "Lucido Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Lucido Trust dated February 16, 2021, fully executed on February 23, 2021, and paid for on February 26, 2020. The Reporting Person may be deemed to have investment power over the Lucido Trust. F3 · ownership.nature: These shares were issued to the Louis C Lucido and Carolyn M. Lucido, or their Successors, as Trustee of the Lucido Family Trust, Dated May 23, 2017 (the "Lucido Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Lucido Trust dated February 16, 2021, fully executed on February 23, 2021, and paid for on February 26, 2020. The Reporting Person may be deemed to have investment power over the Lucido Trust. Read SEC document |
| January 22, 2021 Filed Mar 2, 2021 18:23 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 per share | 2,000 | $1.44 | $2,880.00 |
DisclosureSEC source: 0001477932-21-001163 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,630 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in three transactions at prices ranging from $1.40 to $1.45 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Due to a clerical error in the Form 4 filed by the reporting person on January 5, 2021, the Form 4 incorrectly stated that the reporting person owned 261,926 shares directly. In fact, as of January 5, 2021, the reporting person owned 61,630 shares directly and 200,000 shares indirectly through Louis and Carolyn Lucido CRT LLC (the "LLC"). The difference of 296 shares was due to the aforesaid clerical error, which the reporting person did not discover until now. This Form 4 corrects the aforesaid errors in Table 1, Column 5. Following the reported transactions on January 22, 2021, the reporting person currently owns 63,630 shares directly. Read SEC document |
| September 30, 2020 Filed Oct 13, 2020 22:36 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-20-005862 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,025 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.90. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.